We are live on
!
Find out more
DTC
Deep Track Capital Portfolio holdings
AUM
$6.12B
1-Year Est. Return
144%
This Fund
S&P 500
This Quarter
Est. Return
-3.29%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.59B
AUM Growth
+$431M
(+20%)
Cap. Flow
+$681M
Cap. Flow
% of AUM
26.3%
Top 10 Holdings %
Top 10 Hldgs %
45.87%
Holding
70
New
15
Increased
18
Reduced
13
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Guardant Health
GH
|
+$89.7M |
| 2 |
NovoCure
NVCR
|
+$72.1M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$61.3M |
| 4 |
Axsome Therapeutics
AXSM
|
+$56.6M |
| 5 |
Apogee Therapeutics
APGE
|
+$53.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Immunovant
IMVT
|
+$59.3M |
| 2 |
Structure Therapeutics
GPCR
|
+$23.6M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$14.9M |
| 4 |
Insmed
INSM
|
+$11.4M |
| 5 |
INZY
Inozyme Pharma
INZY
|
+$9.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VIGL
51
DELISTED
Vigil Neuroscience
VIGL
| $9.52M | 0.37% |
1,767,131
-6,278
| -0.4% | -$43.4K |
|
52
Relmada Therapeutics
RLMD
$540M
| $8.51M | 0.33% |
2,837,818
| – | – |
|
|
ATXS
53
DELISTED
Astria Therapeutics
ATXS
| $7.74M | 0.3% |
1,037,873
-659,542
| -39% | -$5.62M |
|
54
10x Genomics
TXG
$5.88B
| $7.54M | 0.29% |
+182,691
| New | +$9.5M |
|
55
Novavax
NVAX
$1.21B
| $7.24M | 0.28% |
+1,000,000
| New | +$7.99M |
|
|
SLRN
56
DELISTED
ACELYRIN
SLRN
| $5.61M | 0.22% |
+551,289
| New | +$11.7M |
|
57
GH Research
GHRS
$1.92B
| $5.02M | 0.19% |
499,400
| – | – |
|
|
SYRS
58
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $3.27M | 0.13% |
+828,485
| New | +$3.1M |
|
59
Scholar Rock
SRRK
$5.88B
| $2.51M | 0.1% |
+353,855
| New | +$2.38M |
|
|
CMPS
60
Compass Pathways
CMPS
$1.47B
| $2.43M | 0.09% |
328,424
-349,936
| -52% | -$3.1M |
|
61
Heron Therapeutics
HRTX
$93.4M
| $2.15M | 0.08% |
2,086,704
| – | – |
|
|
ETNB
62
DELISTED
89bio
ETNB
| $1.41M | 0.05% |
91,078
-412,022
| -82% | -$6.92M |
|
63
Century Therapeutics
IPSC
$364M
| $1.09M | 0.04% |
543,008
-479,884
| -47% | -$1.28M |
|
|
ALLK
64
DELISTED
Allakos
ALLK
| – | – |
-228,277
| Closed | -$995K |
|
|
KYNB
65
CALL
Kyntra Bio
KYNB
$27.4M
| – | – |
-30,588
| Closed | -$2.06M |
|
66
Immunic
IMUX
$178M
| – | – |
-30,831
| Closed | -$774K |
|
67
MiNK Therapeutics
INKT
$51.7M
| – | – |
-32,487
| Closed | -$682K |
|
|
INZY
68
DELISTED
Inozyme Pharma
INZY
| – | – |
-1,644,021
| Closed | -$9.16M |
|
69
MoonLake Immunotherapeutics
MLTX
$1.56B
| – | – |
-108,450
| Closed | -$5.53M |
|
70
Zentalis Pharmaceuticals
ZNTL
$332M
| – | – |
-300,300
| Closed | -$8.47M |
|
Similar funds
AWA
ACM
CIS
AA
JWBC
EMPI
HPG
B
Deep Track Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Deep Track Capital held 70 positions worth $2.59B, up 20% from $2.16B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Deep Track Capital deployed $681M of net new capital in Q3 2023, opening 15 new positions and adding to 18 existing holdings. Its largest new stake was NovoCure: 2,500,000 shares worth $40.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.
On the sell side, the largest reduction was Immunovant, an estimated $59.3M trimmed.
- Deep Track Capital's largest Q3 2023 buy was NovoCure: 2,500,000 shares worth $40.4M.
- Deep Track Capital added most to Guardant Health in Q3 2023, an estimated $89.7M increase.
- Deep Track Capital's biggest Q3 2023 reduction was Immunovant, cutting an estimated $59.3M.
- Deep Track Capital fully exited Inozyme Pharma in Q3 2023, selling an estimated $9.16M.
- Deep Track Capital's ten largest holdings make up 46% of its $2.59B portfolio in Q3 2023.
- Deep Track Capital opened 15 new positions and closed 7 in Q3 2023.
- Deep Track Capital's portfolio value rose 20% quarter-over-quarter to $2.59B.
Based on Deep Track Capital's 13F filing for Q3 2023, filed 14 Nov 2023.